EFFECTS OF AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE ON SERUM-LIPOPROTEINS AND UBIQUINONE-10 LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
EFFECTS OF AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE ON SERUM-LIPOPROTEINS AND UBIQUINONE-10 LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
复制标题
DOI：
10.1056/nejm198108273050902
复制
发表时间：
1981-01-01
影响因子：
158.5
通讯作者：
TAKEDA, R
中科院分区：
文献类型：
--
作者：
MABUCHI, H;HABA, T;TAKEDA, R
研究了3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶的竞争性抑制剂ML 236 B（compactin a fungel metabolite）对7例杂合子家族性高胆固醇血症患者血清脂蛋白和泛醌10水平的影响。ML 236 B剂量为30-60 mg/d，共24 wk。血清胆固醇从390 . ±. 9到303 .+-. 8mg/d（10.1 ±. 0.2至7.88 ±。0.2 mmol/l，平均值±。S.E.M [平均值的SE]; P < 0.001），血清甘油三酯从137 ± 0.001降低至137 ± 0.001。18到87 .+-. 9mg/d（1.55 ±. 0.20至0.98 ±。0.1 mmol/l; P < 0.05）。中密度脂蛋白（IDL）胆固醇、IDL甘油三酯、低密度脂蛋白（LDL）胆固醇和LDL甘油三酯显著降低（分别为P < 0.01、P < 0.02、P < 0.001和P < 0.001）。极低密度脂蛋白（VLDL）胆固醇和甘油三酯或高密度脂蛋白（HDL）胆固醇无显著变化。血清泛醌10水平没有变化，并且泛醌10的LDL水平从0.39 ± 0.01降低了50%。0.07至0.20 ±。0.01μ g/ml（P < 0.05）。未观察到不良反应。ML 236 B可有效降低家族性高胆固醇血症杂合子患者的血清胆固醇，而不降低血清泛醌10。
The effects were studied of ML 236B [compactin a fungel metabolite] a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone 10 in 7 heterozygous patients with familial hypercholesterolemia. ML 236B was given at doses of 30-60 mg/day for 24 wk. Serum cholesterol decreased from 390 .+-. 9 to 303 .+-. 8 mg/d (10.1 .+-. 0.2 to 7.88 .+-. 0.2 mmol/l, mean .+-. S.E.M [SE of mean]; P < 0.001), and serum triglyceride decreased from 137 .+-. 18 to 87 .+-. 9 mg/d (1.55 .+-. 0.20 to 0.98 .+-. 0.1 mmol/l; P < 0.05). Intermediate-density-lipoprotein (IDL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (P < 0.01, P < 0.02, P < 0.001 and P < 0.001, respectively). There were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone 10 levels did not change, and LDL levels of ubiquinone 10 decreased by 50% from 0.39 .+-. 0.07 to 0.20 .+-. 0.01 .mu.g/ml (P < 0.05). No adverse effects were observed. ML 236B is effective in lowering serum cholesterol without lowering serum ubiquinone 10 in heterozygous patients with familial hypercholesterolemia.